Point of Care Diagnostics Market Analysis

The global Point-of-Care (POC) Diagnostics market comprises diagnostic tests, devices, platforms, and consumables that enable medical testing at or near the location where patient care is delivered, rather than requiring samples to be transported to centralized laboratories. These solutions include glucose monitoring, infectious-disease testing, cardiometabolic and cardiac-marker testing, pregnancy and fertility testing, hematology, molecular diagnostics, and other near-patient applications used in hospitals, clinics, pharmacies, emergency departments, community settings, and homes. The market is expanding as healthcare systems increasingly seek rapid, accessible, and decentralized diagnostic services. Key growth drivers include the rising prevalence of chronic diseases such as diabetes and cardiovascular disorders, the continuing burden of infectious diseases, population ageing, growing demand for home-based and self-testing, and technological advances in portable devices, biosensors, molecular assays, digital connectivity, and artificial intelligence. POC diagnostics are important because rapid results can support earlier diagnosis, faster treatment decisions, reduced referrals, improved workflow efficiency, and greater access to healthcare, particularly where conventional laboratory infrastructure is limited. Important associations and stakeholders include the World Health Organization (WHO), which works to strengthen global access, quality, regulation, and use of diagnostics, and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), whose Committee on Point of Care Testing develops educational resources and addresses quality, clinical use, connectivity, and cost-effectiveness. Industry activities include research and development, product launches, regulatory approvals, clinical validation, manufacturing, partnerships, connectivity integration, and expansion of decentralized testing networks. According to the research report, "Global Point of Care Diagnostics Market Outlook, 2031," published by Actual Market Research, the Global Point of Care Diagnostics Market is anticipated to grow at more than 8.01% CAGR from 2026 to 2031.Major companies include Abbott, F. Hoffmann-La Roche, Siemens Healthineers, Danaher, BD, bioMérieux, QIAGEN, QuidelOrtho, Nova Biomedical, Werfen, and OraSure Technologies. Growth opportunities are emerging from home-based testing, decentralized healthcare, telehealth-connected diagnostics, ageing populations, chronic-disease management, infectious-disease surveillance, and expanding healthcare access in Asia-Pacific, Africa, and Latin America.

Technological developments are particularly important: Roche introduced its first point-of-care PCR test for Bordetella infections in 2025, providing results in approximately 15 minutes, while the company reported introducing two instrument platforms, six digital solutions, and 53 new tests across its Diagnostics business during 2025. Abbott also operates a substantial rapid-diagnostics business spanning consumer testing, molecular testing, and data-centric diagnostics; its 2025 results reported USD 606 million in Point-of-Care sales, including USD 422 million in the U.S. and USD 184 million internationally. From a supply-chain perspective, the market involves raw-material and component suppliers, assay and reagent manufacturers, instrument developers, contract manufacturers, packaging and sterilization providers, regulatory and quality-control processes, distributors, hospitals, clinics, pharmacies, laboratories, and home users. Supply chains increasingly emphasize localized manufacturing, dependable reagent availability, digital connectivity, cold-chain requirements where applicable, regulatory compliance, and scalable distribution to decentralized testing sites. Opportunities therefore extend beyond diagnostic devices themselves to consumables, software, connectivity, logistics, and integrated diagnostic-service models. .

Market Dynamic

Point of Care DiagnosticsSegmentation

Cardiometabolic monitoring kits are the fastest-growing product segment because the global burden of diabetes, hypertension, cardiovascular disease, and related metabolic risk factors is increasing the need for repeated, accessible monitoring outside conventional laboratory settings.

The clinical importance of cardiometabolic monitoring kits is closely tied to the fact that diabetes and cardiovascular conditions require ongoing measurement rather than a single diagnostic event. WHO reports that about 830 million people worldwide were living with diabetes in 2022, with prevalence increasing particularly rapidly in low- and middle-income countries, while more than half of people with diabetes were not receiving medication in that year. WHO also identifies regular blood-glucose control, blood-pressure and lipid control, and screening for complications as important components of diabetes management. This creates a practical role for monitoring technologies that can be used repeatedly by healthcare workers or, where appropriate, by patients themselves. The broader cardiovascular burden adds another layer to this requirement because blood pressure, glucose, lipids, obesity and kidney-related indicators often need to be assessed together when managing cardiometabolic risk. WHO describes diagnostics as essential not only for diagnosis but also for screening, case management, monitoring and treatment of noncommunicable diseases. Point-of-care technologies are particularly relevant because they can bring these measurements closer to the patient and reduce reliance on centralized laboratories for selected tests. WHO's essential diagnostic framework explicitly includes blood glucose measurement, glucose meters, HbA1c testing, blood-pressure measurement and urine-based tests among technologies suitable for community and primary-care environments. This is significant because primary healthcare is often the first contact between patients and the health system, especially for chronic disease screening and follow-up. Cardiometabolic monitoring kits can also support longitudinal care by enabling repeated measurements during consultations, home monitoring, pharmacy-based services or community programmes, depending on the product and regulatory indication. WHO's self-care guidance specifically recognizes self-monitoring of blood glucose and blood pressure as established self-care interventions for appropriate populations.

Lateral flow assays are the fastest-growing technology/platform segment because their rapid, portable and relatively simple format allows diagnostic testing to move into primary care, community, pharmacy and self-testing environments.

Lateral flow assays have become an important foundation of decentralized diagnostics because they can deliver a visible or instrument-assisted result without the infrastructure normally required for a conventional laboratory workflow. WHO describes lateral-flow rapid diagnostic tests as playing a vital role in global health for diseases including malaria, HIV and COVID-19, and notes that visually interpreted rapid diagnostic tests can meet the practical characteristics required for use at the lowest levels of healthcare and in self-testing. This operating model is especially important in settings where patients may live far from laboratories or where healthcare workers need information during the same encounter. WHO's 2025 guidance on rapid diagnostic accessibility covers professional-use and self-testing formats and specifically includes tests for HIV, malaria, tuberculosis, SARS-CoV-2, syphilis, hepatitis B, hepatitis C, urine dipsticks, G6PD deficiency and pregnancy. The breadth of applications demonstrates why lateral-flow technology is not dependent on a single disease area. Its small footprint, relatively limited equipment requirements and rapid operating procedure allow manufacturers to adapt the format to different analytes and clinical needs. The technology can be used in hospitals and clinics, but its practical advantages become particularly evident when testing needs to be performed in pharmacies, community facilities, mobile services or homes. WHO's essential diagnostics work explicitly distinguishes tests suitable for community settings and facilities without laboratories, reinforcing the role of decentralized formats in expanding access to diagnosis. The COVID-19 experience also demonstrated the operational value of rapid antigen testing, with WHO recognizing self-testing as a way for individuals to collect specimens, perform a simple rapid test and interpret results at a chosen time and location. Lateral-flow assays can therefore reduce the logistical dependence on specimen transport and centralized processing for selected diagnostic applications. However, rapid does not mean universally definitive: WHO notes that incorrect performance or interpretation can compromise test utility, which is why quality, instructions, training where required, and appropriate confirmation pathways remain important.

Home care and self-testing are the fastest-growing end-user segment because diagnostic and monitoring technologies are increasingly being designed to let people obtain selected health information outside formal healthcare facilities while remaining connected to professional care.

The expansion of home care and self-testing is supported by a clear change in how selected diagnostic activities can be delivered. WHO defines self-care as the ability of individuals, families and communities to promote and maintain health, prevent disease and cope with illness with or without the support of a health worker, and explicitly includes diagnostics and monitoring devices within self-care interventions. Examples identified by WHO include self-monitoring of blood glucose for diabetes, self-monitoring of blood pressure, pregnancy testing, HIV self-testing and other diagnostic interventions. This means home-based diagnostics are not simply consumer conveniences; they can form part of structured health interventions when appropriate safeguards and referral pathways exist. The model is particularly relevant to chronic diseases because patients may need measurements repeatedly between clinical appointments. For diabetes, WHO identifies blood-glucose measurement as a basic technology that should be available in primary healthcare, while its self-care guidance supports self-monitoring of blood glucose for people with diabetes when clinically appropriate. Home testing can also be valuable when geographic distance, transportation, work schedules, mobility limitations or healthcare-system congestion make frequent facility visits difficult. WHO's 2025 rapid diagnostic guidance recognizes both professional-use and self-testing environments and emphasizes accessibility and usability for older adults, people with disabilities and other users who may encounter difficulties with small text, confusing symbols or physical handling. This is important because the growth of self-testing depends not merely on making a test available but on ensuring that users can operate it correctly and understand what the result means. Home diagnostics also complement rather than replace healthcare services. WHO's guidance explicitly states that self-care does not replace the health system or healthcare workers but complements them. A home test can therefore function as an early screening tool, a monitoring instrument, or a way to collect information that is subsequently discussed with a healthcare professional.

Prescription-based products are the fastest-growing mode-of-purchase segment because many advanced point-of-care tests are increasingly incorporated into professionally managed diagnostic and treatment pathways where clinical selection, interpretation and follow-up are required.

Prescription-based point-of-care diagnostics are particularly relevant when the result is intended to guide a medical decision rather than simply provide a consumer with preliminary information. WHO describes diagnostics as essential for prevention, screening, diagnosis, case management, monitoring and treatment, meaning that diagnostic testing is closely connected to clinical decision-making throughout the patient pathway. As point-of-care technology expands beyond basic screening into more clinically consequential applications, professional involvement becomes increasingly important. A healthcare professional may need to determine whether testing is appropriate, select the relevant assay, collect the specimen correctly, interpret the result in combination with symptoms and medical history, and decide whether treatment, referral or confirmatory testing is required. WHO's Essential Diagnostics List reflects this distinction by organizing diagnostics according to different healthcare settings, including community and primary-care environments as well as facilities with laboratory capabilities. The list includes technologies for diabetes, infectious diseases, pregnancy, kidney disease, hematology and other clinical applications, demonstrating that point-of-care diagnostics can be integrated into structured healthcare pathways rather than functioning solely as consumer products. Prescription-oriented products are also relevant to chronic conditions where testing results may influence medication adjustment or follow-up. Diabetes management, for example, involves glucose control, blood-pressure and lipid management, and screening for complications, all of which require appropriate clinical context. Similarly, rapid infectious-disease tests can influence treatment and infection-control decisions, making appropriate patient selection and result interpretation important. WHO's 2025 guidance on rapid diagnostic tests distinguishes professional-use testing from self-testing and emphasizes accessibility, usability and correct performance across both environments. Professional procurement can also support standardized testing protocols, quality assurance, staff training and integration into clinical workflows. This becomes important as point-of-care testing moves into more complex applications where errors can have consequences for treatment. Prescription-based purchasing should not be interpreted as meaning that all point-of-care diagnostics require prescriptions; many approved self-tests and OTC products remain available for suitable applications. Rather, the increasing role of prescription-based products can be explained by the expanding clinical sophistication of point-of-care testing and its integration into formal care pathways.

Urine is the fastest-growing sample segment because it offers simple, non-invasive collection and supports a broad range of decentralized tests covering metabolic, kidney, urinary, reproductive and infectious-health applications.

Urine is particularly suitable for point-of-care diagnostics because specimen collection generally does not require needles, venous access or specialized phlebotomy equipment, allowing testing to be performed relatively easily in clinics, community settings and homes when the specific product is authorized for those environments. WHO's Essential Diagnostics List includes several urine-based tests suitable for community and health settings without laboratories, including albumin, bilirubin, glucose, ketones and multiparameter urinalysis strips. This breadth is important because urine is not tied to one diagnostic application. Urinalysis can help identify abnormalities associated with urinary tract conditions, kidney disease and metabolic disorders, while urine glucose and ketone testing can contribute to diabetes-related assessment. WHO's essential diagnostics framework specifically identifies urine dipsticks for albumin to detect or monitor kidney disease, ketones for diabetic ketoacidosis, and multiparameter urine strips for urinary tract infection assessment. Pregnancy testing provides another established urine-based point-of-care application, with WHO listing human chorionic gonadotropin rapid tests in dipstick and cassette formats among diagnostics suitable for decentralized use. The specimen's accessibility also aligns with the wider movement toward self-testing and community diagnostics. WHO's 2025 rapid diagnostic guidance includes urine dipstick testing within its scope and emphasizes that tests intended for professional and self-testing should be accessible and usable by diverse populations. Urine testing can therefore be incorporated into primary-care workflows where laboratory resources are limited, helping health workers obtain basic diagnostic information during a patient encounter. The technology is particularly compatible with dipsticks because the sample can be applied directly to a strip containing multiple reagent areas, allowing several parameters to be assessed from one specimen. WHO's primary-care diagnostic materials identify urine dipsticks alongside blood glucose and other basic tests as appropriate technologies for settings with limited laboratory infrastructure.

Point of Care Diagnostics Market Regional Insights

Asia Pacific is the fastest-growing regional segment because the region combines a very large population with substantial chronic and infectious disease needs, expanding primary healthcare infrastructure, and significant demand for accessible diagnostics outside centralized laboratories.

Asia Pacific has several structural characteristics that support rapid expansion of point-of-care diagnostics, beginning with the scale and diversity of its population and healthcare systems. The region contains countries with highly developed tertiary-care networks alongside areas where primary-care facilities have limited laboratory infrastructure, making decentralized diagnostic technologies relevant across very different healthcare environments. WHO's Essential Diagnostics List was specifically developed to help countries identify tests appropriate for different levels of care, including community settings and facilities without laboratories, with the objective of improving access to essential diagnosis and supporting universal health coverage. Chronic disease is a major component of the underlying need. WHO reports that diabetes has increased substantially worldwide, with prevalence rising more rapidly in low- and middle-income countries, many of which are located in Asia Pacific. Diabetes management requires repeated glucose measurement, while cardiovascular and metabolic risk management also involves blood-pressure, lipid, kidney and other assessments. WHO's essential diagnostic framework includes glucose meters, HbA1c, urine tests and other technologies that can be used in community and primary-care environments. The region also carries a substantial burden of infectious diseases for which rapid diagnosis can be important. WHO identifies lateral-flow rapid diagnostic tests as important tools for diseases such as malaria, HIV and COVID-19 and notes that their characteristics can allow use at low levels of healthcare and in self-testing. This combination of communicable and noncommunicable disease needs creates a wide application base for point-of-care technologies. Healthcare decentralization is another factor.